« Back
Home /
Bozitinib

Bozitinib

Item no.	HY-125017-10mM
Manufacturer	MedChem Express
CASRN	1440964-89-5
Amount	10mM/1mL
Quantity options	100 mg 10mM/1mL 10 mg 1 mg 25 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	98.98
Formula	C20H15F3N8
Citations	[1]Hu H, et al. Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. Cell. 2018 Nov 29;175(6):1665-1678.e18.
Smiles	CN1N=C2C=C(F)C(C(C3=NN=C4C=CC(C5=CN(C6CC6)N=C5)=NN43)(F)F)=CC2=C1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	PLB-1001; CBT-101; Vebreltinib
Similar products	PLB-1001, CBT-101
Available
Product Description	Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily[1].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	424.38
Clinical Information	Phase 3
Manufacturers Research Area	Cancer
Solubility	DMSO : 50 mg/mL (ultrasonic)
Target	c-Met/HGFR
Manufacturers Target	c-Met/HGFR
Manufacturers Pathway	Protein Tyrosine Kinase/RTK
Manufacturers Product type	Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-125017-10mM-safety-datasheet.pdf